WallStSmart

Intuitive Surgical Inc (ISRG)vsAnbio Biotechnology Class A Ordinary Shares (NNNN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Intuitive Surgical Inc generates 145339% more annual revenue ($10.06B vs $6.92M). NNNN leads profitability with a 37.2% profit margin vs 28.4%. ISRG trades at a lower P/E of 59.9x. ISRG earns a higher WallStSmart Score of 62/100 (C+).

ISRG

Buy

62

out of 100

Grade: C+

Growth: 8.0Profit: 9.0Value: 4.7Quality: 7.8
Piotroski: 4/9Altman Z: 6.18

NNNN

Hold

37

out of 100

Grade: F

Growth: 5.3Profit: 8.0Value: 3.0Quality: 7.8
Piotroski: 4/9Altman Z: 9.08
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ISRGSignificantly Overvalued (-78.8%)

Margin of Safety

-78.8%

Fair Value

$262.88

Current Price

$469.98

$207.10 premium

UndervaluedFair: $262.88Overvalued
NNNNSignificantly Overvalued (-3894.1%)

Margin of Safety

-3894.1%

Fair Value

$0.68

Current Price

$23.76

$23.08 premium

UndervaluedFair: $0.68Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ISRG5 strengths · Avg: 9.2/10
Operating MarginProfitability
30.2%10/10

Strong operational efficiency at 30.2%

Altman Z-ScoreHealth
6.1810/10

Safe zone — low bankruptcy risk

Market CapQuality
$167.61B9/10

Large-cap with strong market position

Profit MarginProfitability
28.4%9/10

Keeps 28 of every $100 in revenue as profit

Revenue GrowthGrowth
18.8%8/10

18.8% revenue growth

NNNN3 strengths · Avg: 10.0/10
Profit MarginProfitability
37.2%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
73.5%10/10

Strong operational efficiency at 73.5%

Altman Z-ScoreHealth
9.0810/10

Safe zone — low bankruptcy risk

Areas to Watch

ISRG3 concerns · Avg: 3.3/10
PEG RatioValuation
2.434/10

Expensive relative to growth rate

Price/BookValuation
9.4x4/10

Trading at 9.4x book value

P/E RatioValuation
59.9x2/10

Premium valuation, high expectations priced in

NNNN4 concerns · Avg: 2.8/10
EPS GrowthGrowth
2.8%4/10

2.8% earnings growth

Market CapQuality
$1.02B3/10

Smaller company, higher risk/reward

P/E RatioValuation
386.5x2/10

Premium valuation, high expectations priced in

Price/BookValuation
37.7x2/10

Trading at 37.7x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : ISRG

The strongest argument for ISRG centers on Operating Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 28.4% and operating margin at 30.2%. Revenue growth of 18.8% demonstrates continued momentum.

Bull Case : NNNN

The strongest argument for NNNN centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 37.2% and operating margin at 73.5%.

Bear Case : ISRG

The primary concerns for ISRG are PEG Ratio, Price/Book, P/E Ratio. A P/E of 59.9x leaves little room for execution misses.

Bear Case : NNNN

The primary concerns for NNNN are EPS Growth, Market Cap, P/E Ratio. A P/E of 386.5x leaves little room for execution misses.

Key Dynamics to Monitor

ISRG profiles as a growth stock while NNNN is a declining play — different risk/reward profiles.

ISRG is growing revenue faster at 18.8% — sustainability is the question.

ISRG generates stronger free cash flow (730M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ISRG scores higher overall (62/100 vs 37/100), backed by strong 28.4% margins and 18.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Intuitive Surgical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.

Anbio Biotechnology Class A Ordinary Shares

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.

Want to dig deeper into these stocks?